Gyre Therapeutics (GYRE) Expected to Post Earnings on Friday

Gyre Therapeutics (NASDAQ:GYRE) is expected to be releasing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $28.40 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The firm had revenue of $29.11 million for the quarter, compared to the consensus estimate of $26.49 million. On average, analysts expect Gyre Therapeutics to post ($0.61) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $4.44 on Wednesday. Gyre Therapeutics has a 52 week low of $4.26 and a 52 week high of $9.14. The stock has a market capitalization of $495.10 million, a P/E ratio of -21.14 and a beta of 2.14. The stock has a fifty day moving average of $6.65 and a 200-day moving average of $6.96.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Wall Street Zen downgraded Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Gyre Therapeutics has an average rating of “Reduce”.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.